Copyright 2002 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2002
The findings from 3 case-control studies in a recent issue of the ARCHIVES1- 3 do not eliminate the possibility that cyclooxygenase (COX)-2 inhibitors increase the risk of myocardial infarction (MI) and other thrombotic cardiovascular events by altering the balance between prostacyclin and thromboxane.4,5 The studies suggest that naproxen may modestly decrease the risk of MI.
Goldstein MR. Cyclooxygenase-2 Inhibitors and Myocardial Infarction. Arch Intern Med. 2002;162(22):2639. doi: